title: [Antithrombotic therapy and pregnancy].
abstract: The incidence of venous thromboembolism (VTE) during pregnancy is about one event per 1000 pregnancies and placenta-mediated pregnancy complications (PC) occurred in 15%. Knowing the biological combined with clinical risk factors would help to prevent problems during the pregnancy. Several antithrombotic therapies exist, including very recent ones but LMWH and aspirin are still molecules of choice. The women should be assessed for VTE and PC risk in order to improve the outcome.
authors.affiliation: CHU de Saint-Étienne, hôpital Nord, département d'obstétrique et gynécologie, 42270 Saint-Priest-en-Jarez, France; Université Jean-Monnet, EA 3065 groupe de recherche sur la thrombose, Saint-Étienne, France. Electronic address: celine.chauleur@chu-st-etienne.fr.
authors.forename: Céline
authors.initials: C
authors.lastname: Chauleur
authors.forename: Tiphaine
authors.initials: T
authors.lastname: Raia
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Gris
mesh_terms: D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control*; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents